Influenza

Bibliography

• Influenza immunisation CMO'S UPDATE 23 (August1999):6.
   Google Scholar
• ASHLEY J, SMITH T, DUNNEL K: Deaths in Great Britainassociated with the influenza epidemic of 1989/90. In: Population Trends: Office of Population Censuses and Surveys. HM Stationary Office, London, UK (1991) 65:16–20.
   Google Scholar
• CDC: Prevention and control of influenza: recommen-dations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 48(No.RR-4) (April 1999) 1–24.
   Google Scholar
• WANG C, TAKEUCHI K, PINTO LH, LAMB RA: Ion channelactivity of influenza A virus My protein: characterisa-tion of amantadine block. J. Virol. (1993) 67:5585–5594.
   PubMed Web of Science ®Google Scholar
• CHIZMAKOV IV, GERAGHTY FM, OGDEN DC, HAYHURST A, ANTONION M, HAY AJ: Selective proton permeability and pH regulation of the influenza virus My channel expressed in mouse erythroleukemia cells. J. Physic)]. (1996) 494:329–336.
   Google Scholar
• DUFF KC, GILCHRIST PJ, SAXENA AM, BRADSHAW JP: Neutron diffraction reveals the site of amantadine blockade in the influenza A My ion channel. Virology (1994) 202:287–293.
   PubMedGoogle Scholar
• BLEIDNER WE, HARMON JB, HEWES WE, LYNES TE, HERMANN EC: Absorption, distribution and excretion of amantadine hydrochloride. J. Pharmacol Exp. Ther. (1965) 150:484–490.
   PubMed Web of Science ®Google Scholar
• SMITH CB, PURCELL RH, CHANOCK RM: Effect ofamantadine hydrochloride on parainfluenza Type 1 virus infections in adult volunteers. Am. Rev. Respir. Dis. (1967) 95:689–692.
   PubMedGoogle Scholar
• HAYDEN FG, MINOCHA A, SPYKER DA, HOFFMAN H: Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. (1985) 28:216–221.
   PubMed Web of Science ®Google Scholar
• TOMINACK RL, WILLS RJ, GUSTAVSON LE, HAYDEN FG.: Multiple-dose pharmacokinetics of rimantadine in elderly adults. Antimicrob. Agents Chemother. (1988) 32:1813–1819.
   PubMedGoogle Scholar
• DOUGLAS RG, JR.: Drug therapy: prophylaxis andtreatment of influenza. N. Engl. J. Med. (1990) 322:443–450.
   PubMedGoogle Scholar
• AOKI FY, SITAR DS: Amantadine kinetics in healthyelderly men: implications for influenza prevention. Clin. Pharmacol. Ther. (1985) 37:137–44.
   PubMedGoogle Scholar
• WINTERMEYER SM, NAHATA MC: Rimantadine: a clinical perspective. Ann. Pharmacother. (1995) 29:299–310.
   PubMed Web of Science ®Google Scholar
• DOUGLAS RG, JR.: Drug therapy: prophylaxis andtreatment of influenza. N. Engl. J. Merl. (1990) 322:443–450.
   PubMedGoogle Scholar
• HAYDEN FG, BELSHE RB, CLOVER RD, HAY AJ, OAKESMG, SOO W: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl. J. Med. (1989) 321:1696–1702.
   PubMed Web of Science ®Google Scholar
• PAYLER DK, PURDHAM PA: Influenza A prophylaxis with amantadine in a boarding school. Lancet (1984) 1:502–504.
   PubMedGoogle Scholar
• DOLIN R, REICHMAN RC, MADORE HP, MAYNARD R, LINTON PN, WEBBER-JONES J: A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl. J. Med. (1982) 307:580–584.
   PubMed Web of Science ®Google Scholar
• SEARS SD, CLEMENTS ML: Protective efficacy oflow-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob. Agents Chemother. (1987) 31:1470–1473.
   PubMed Web of Science ®Google Scholar
• GUAY DRP: Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging (1994) 5:8–19.
   PubMedGoogle Scholar
• TOMINACK RL, HAYDEN FG: Rimantadine hydrochlo-ride and amantadine hydrochloride use in influenza A virus infections. Infect. Dis. Clin. North. Am. (1987) 1:459–478.
   PubMedGoogle Scholar
• COCHRAN KW, MAASAB HF, TSUNODA A, BERLIN BS: Studies on the antiviral activity of amantadine hydrochloride. Ann. NY Acad. Sci. (1965) 130:432–439.
   PubMed Web of Science ®Google Scholar
• TSONODA A, MAASAB HF, COCHRAN KW, EVELAND WC: Antiviral activity of a-methyl-l-adamantane--methylamine hydrochloride. Antimicrob. Agents Chemother. (1965) 5:553–560.
   PubMedGoogle Scholar
• ILYENKO VI: The study of formation of amantadine-and rimantadine-resistant variants of influenza. Vaprosy. Virusol. (1975) 2:199–202.
   Google Scholar
• BELSHE RB, SMITH MH, HALL CB, BETTS R, HAY AJ: Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Vim]. (1988) 62:1508–1512.
   Google Scholar
• HAYDEN FG, COUCH RB: Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Rev. Med. Virol. (1992) 2:89–96.
   Google Scholar
• HAYDEN FG, HAY AJ: Emergence and transmission ofinfluenza A viruses resistant to amantadine and rimantadine. Curr. Top. MicrobioL Immunol. (1992) 176:119–130.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, SPERBER SJ, BELSHE RB, CLOVER RD, HAY AJ, PYKE S: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine Antimicrob. Agents Chemother. (1991) 35:1741–1747.
   PubMed Web of Science ®Google Scholar
• CALFEE DR, HAYDEN FG: New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs (1998) 56:537–553.
   PubMedGoogle Scholar
• ••Thorough review of neuraminidase inhibitors.
   Google Scholar
• VON ITZSTEIN M, WU WY, KOK GB et al: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418–423.
   PubMed Web of Science ®Google Scholar
• WOODS JM, BETHELL RC, COATES JAV et al.: 4 -guanidino-2, 4 -dideoxy-2,3 -dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. (1993) 37: 1473–1479.
   PubMed Web of Science ®Google Scholar
• LIU C, EICHELBERGER MC, COMPANS RW, AIR GM: Influenza Type A virus neuraminidase does not play a role in viral entry, replication, assembly or budding. J. Virol. (1995) 69:1099–1106.
   PubMed Web of Science ®Google Scholar
• PALESE P, COMPANS RW: Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANO mechanism of action. J. Gen. Virol. (1976) 33:159–163.
   PubMed Web of Science ®Google Scholar
• CASS LMR, EFTHYMIOPOULOS C, BYE A: Pharmacoki-netics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 0:1–11.
   Google Scholar
• CASS LMR, EFTHYMIOPOULOS C, MARSH J, BYE A: Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Gun. Pharmacokinet. (1999) 36\(Suppl. 0:13–19.
   Google Scholar
• CASS LMR, BROWN J, PICKFORD M et al.: Pharmacoscin-tigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 0:21–31.
   Google Scholar
• BERGSTROM M, CASS LMR, VALIND S et al: Deposition and disposition of 11C zanamivir following admini-stration as an intranasal spray-evaluation with positron emission tomography. Clin. Pharmacokinet. (1999) 36\(Suppl. 1):33–39.
   Google Scholar
• •Article revealing a novel use of PET scan.
   Google Scholar
• MONTO AS, ROBINSON DP, HERLOCHER ML, HINSON JM, JR., ELLIOTT MJ, CRISP A: Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA (1999) 282:31–35.
   Google Scholar
• HAYDEN FG, OSTERHAUS ADME, TREANOR JJ et al., FOR THE GG167 INFLUENZA STUDY GROUP: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl. J. Med. (1997) 337:874–880.
   PubMedGoogle Scholar
• DANIEL MJ, BARNETT JM, PEARSON BA: The low potential for drug interactions with zanamivir. Pharmacokinet. (1999) 36\(Suppl. 0:41–50.
   Google Scholar
• HAYDEN FG, LOBO M, HUSSEY EK, EASON C: Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: BROWN LE, HAMPSON AW, WEBSTER RG, eds. Options for Control of Influenza HL Amsterdam. Elsevier Science BV (1996):718–725.
   Google Scholar
• HAYDEN FG, TREANOR JJ, BETTS RF, LOBO M, ESINHART JD, HUSSEY EK: Safety and efficacy of the neuramini-dase inhibitor GG167 in experimental human influenza. JAMA (1996) 275:295–299.
   PubMed Web of Science ®Google Scholar
• MONTO AS, FLEMING DM, HENRY D et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Inf. Dis. (1999) 180:254–261.
   PubMed Web of Science ®Google Scholar
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) study group. Lancet (1998) 352:1877–1881.
   PubMed Web of Science ®Google Scholar
• MCKIMM-BRESCHKIN JL, BLICK TJ, SAHASRABUDHE A et al.: Generation and characterisation of variants of NINS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. (1996) 40:40–46.
   PubMed Web of Science ®Google Scholar
• WEBSTER A, BOYCE M, EDMUNDSON S, MILLER: Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of anti haemagglutinin antibodies in the serum of healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 0:51–58.
   Google Scholar
• GUBAREVA LV, BETHELL R, HART GJ, MURTI KG, PENN CR, WEBSTER RG: Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. (1996) 70:1818–1827.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, TAI CY, ESCARPE PA et al.: Oral administra-tion of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. (1998) 42(3):640–646.
   PubMed Web of Science ®Google Scholar
• SIDWELL RW, HUFFMAN JH, BARNARD DL et al.: Inhibi-tion of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. (1998) 37:107–120.
   PubMed Web of Science ®Google Scholar
• KIM CU, LEW W, WILLIAMS MA et al.: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbox-ylic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. (1997) 119:681–690.
   PubMed Web of Science ®Google Scholar
• LI W, ESCARPE PA, EISENBERG EJ et al.: Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. (1998) 42:647–653.
   PubMed Web of Science ®Google Scholar
• WINQUIST AG, FUKUDA K, BRIDGES CB, COX NJ: Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR 48 (RR14) (December 1999) 1–9.
   Google Scholar
• ••Recent elaborate overview of neuraminidase inhibitors.
   Google Scholar
• WOOD ND, AITKEN M, SHARP S et al.: Tolerability andpharmacokinetics of the influenza neuraminidase inhibitor Ro-64-0802 (GS4071) following oral admini-stration of the prodrug Ro-64-0796 (GS4104) to the healthy male volunteers. 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada (28 Sep - 1 Oct 1997). Abstract A–123.
   Google Scholar
• HE G, MASSARELLA J, AITKEN M et al.: The pharmacoki-netics and safety of the oral neuraminidase inhibitor Ro 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects [Abstract P17]. j Antimicrob. Chemother. (1999) 44 (Suppl. A) :44.
   Google Scholar
• HAYDEN FG, TREANOR JJ, FRITZ RS et al: Use of the oralneuraminidase inhibitor oseltamivir in experimental human influenza. JAMA (1999) 282:1240–1246.
   PubMed Web of Science ®Google Scholar
• TREANOR JJ, VROOMAN PS, HAYDON FG, KINNERSLY N,WARD P, MILLS RG, ON BEHALF OF THE US ORAL NEURAMINADASE STUDY GROUP: Efficacy of oral GS4104 in treating acute influenza. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract LB–4.
   Google Scholar
• AOKI F, OSTERHAUS A, RIMMELZWAAN G, KINNERSLEYN, WARD P, ON BEHALF OF THE US ORAL NEURAMINA-DASE STUDY GROUP: Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (24–27 September 1998). Abstract LB–5.
   Google Scholar
• •A detailed abstract.
   Google Scholar
• HAYDEN FG, ATMAR RL, SCHILLING M et al: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl. J Med. (1999) 341:1336–1343.
   PubMed Web of Science ®Google Scholar
• •A good article showing a long-term yet safe use.
   Google Scholar